Novartis AG
NVS
$111.88
$0.460.41%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 13.15B | 12.82B | 12.51B | 11.83B | 11.42B |
| Total Other Revenue | 405.00M | 349.00M | 360.00M | 291.00M | 353.00M |
| Total Revenue | 13.56B | 13.17B | 12.87B | 12.12B | 11.78B |
| Cost of Revenue | 3.31B | 3.24B | 3.17B | 3.09B | 2.57B |
| Gross Profit | 10.24B | 9.93B | 9.70B | 9.03B | 9.21B |
| SG&A Expenses | 3.50B | 3.13B | 3.09B | 2.84B | 3.42B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 112.00M | 8.00M | -7.00M | 222.00M | -478.00M |
| Total Operating Expenses | 9.50B | 8.76B | 8.57B | 8.39B | 5.72B |
| Operating Income | 4.06B | 4.41B | 4.30B | 3.73B | 6.06B |
| Income Before Tax | 3.29B | 3.39B | 3.84B | 3.13B | 2.38B |
| Income Tax Expenses | 465.00M | 200.00M | 595.00M | 441.00M | -261.00M |
| Earnings from Continuing Operations | 2.82B | 3.19B | 3.25B | 2.69B | 2.64B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 5.84B |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -2.00M | 4.00M | -- | -- | 0.00 |
| Net Income | 2.82B | 3.19B | 3.25B | 2.69B | 8.48B |
| EBIT | 4.06B | 4.41B | 4.30B | 3.73B | 6.06B |
| EBITDA | 4.16B | 5.50B | 5.36B | 4.82B | 7.15B |
| EPS Basic | 1.42 | 1.59 | 1.60 | 1.32 | 4.14 |
| Normalized Basic EPS | 1.27 | 1.31 | 1.26 | 1.09 | 1.84 |
| EPS Diluted | 1.41 | 1.57 | 1.59 | 1.31 | 4.11 |
| Normalized Diluted EPS | 1.26 | 1.30 | 1.26 | 1.09 | 1.83 |
| Average Basic Shares Outstanding | 1.99B | 2.01B | 2.03B | 2.04B | 2.05B |
| Average Diluted Shares Outstanding | 2.00B | 2.03B | 2.05B | 2.06B | 2.07B |
| Dividend Per Share | 3.86 | -- | -- | -- | 3.92 |
| Payout Ratio | 0.00% | -- | 74.46% | 193.71% | 0.00% |
